文献速递核素与放射性配体治疗肿瘤 PET/CT

钬-166微球放射栓塞治疗神经内分泌肿瘤肝转移的剂量-效应关系

Dose-effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-19

单中心回顾性研究纳入25例患者27次钬-166微球放射栓塞治疗、共114个神经内分泌肿瘤肝转移灶,分析肿瘤吸收剂量与病灶客观缓解、健康肝组织剂量与毒性的关系及生存。结果显示缓解者平均肿瘤剂量118 Gy高于未缓解者68 Gy(P=0.01),ROC确定86 Gy为最佳阈值(敏感度83%、特异度81%),肿瘤剂量≥120 Gy时缓解可能性最高(90%);中位无进展生存期15个月,中位总生存期未达到。

要点

  • 缓解者平均肿瘤吸收剂量118 Gy vs 未缓解者68 Gy(P=0.01),呈明确剂量-效应关系。
  • ROC分析确定86 Gy阈值,敏感度83%、特异度81%;肿瘤剂量≥120 Gy时缓解可能性最高(90%)。
  • 未发现明确的健康肝组织剂量-毒性关系;中位无进展生存期15个月,中位总生存期未达到。

核心结论

  • 本研究在真实世界环境中证实钬-166微球放射栓塞治疗神经内分泌肿瘤肝转移安全有效,并显示明确的剂量-效应关系。
  • 作者认为未来研究应以肿瘤吸收剂量≥120 Gy为目标,该剂量可预测缓解;未能建立剂量-毒性关系。

研究设计与样本

  • 单中心、回顾性研究,纳入接受钬-166微球放射栓塞治疗的神经内分泌肿瘤肝转移患者,要求治疗后SPECT/CT及3个月随访时增强CT或MRI影像。
  • 共纳入25例患者的27次治疗,合计114个肿瘤;中位随访14个月(范围3–82个月)。
  • 治疗后SPECT/CT用于计算肿瘤吸收剂量(Dt)和全肝健康组织吸收剂量(Dh)。
  • 临床和实验室毒性按常见不良事件评价标准(CTCAE)第5版在基线和3个月随访时分级;疗效按RECIST 1.1判定。
  • 将肿瘤剂量和健康肝剂量分别与基于病灶的客观缓解和基于患者的毒性进行相关性分析;采用Kaplan-Meier分析无进展生存期(PFS)和总生存期(OS)。

主要发现

  • 未缓解者平均肿瘤吸收剂量为68 Gy,缓解者为118 Gy,P=0.01。
  • ROC分析确定86 Gy具有最高敏感度和特异度,分别为83%和81%。
  • 达到肿瘤吸收剂量≥120 Gy时获得缓解的可能性最高(90%)。
  • 16例患者出现1–2级临床毒性,仅1例出现3级毒性;未发现明确的健康肝剂量-毒性关系。
  • 中位无进展生存期为15个月(95%CI [10.2;19.8]),中位总生存期未达到。

关键数值与推荐

  • 肿瘤吸收剂量≥120 Gy与获得缓解的最高可能性(90%)相关。
  • ROC分析确定的肿瘤吸收剂量阈值为86 Gy,敏感度83%、特异度81%。

临床怎么用

  • 作者认为未来研究应以肿瘤吸收剂量≥120 Gy为目标,该剂量可预测缓解。
  • 本研究在真实世界环境中证实钬-166微球放射栓塞治疗神经内分泌肿瘤肝转移安全有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Aim of this study was to investigate a dose-response relationship, dose-toxicity relationship, progression free survival (PFS) and overall survival (OS) in neuroendocrine tumour liver metastases (NELM) treated with holmium-166-microspheres radioembolization ([166Ho]-radioembolization). MATERIALS AND METHODS: Single center, retrospective study included patients with NELM that received [166Ho]-radioembolization with post-treatment SPECT/CT and CECT or MRI imaging for 3 months follow-up. Post-treatment SPECT/CT was used to calculate tumour (Dt) and whole liver healthy tissue (Dh) absorbed dose. Clinical and laboratory toxicity was graded by Common Terminology Criteria for Adverse Events (CTCAE), version 5 at baseline and three-months follow-up. Response was determined according to RECIST 1.1. The tumour and healthy doses was correlated to lesion-based objective response and patient-based toxicity. Kaplan Meier analyses were performed for progression free survival (PFS) and overall survival (OS). RESULTS: Twenty-seven treatments in 25 patients were included, with a total of 114 tumours. Median follow-up was 14 months (3 - 82 months). Mean Dt in non-responders was 68 Gy versus 118 Gy in responders, p = 0.01. ROC analysis determined 86 Gy to have the highest sensitivity and specificity, resp. 83% and 81%. Achieving a Dt of ≥ 120 Gy provided the highest likelihood of response (90%) for obtaining response. Sixteen patients had grade 1-2 clinical toxicity and only one patient grade 3. No clear healthy liver dose-toxicity relationship was found. The median PFS was 15 months (95% CI [10.2;19.8]) and median OS was not reached. CONCLUSION: This study confirms the safety and efficacy of [166Ho]-radioembolization in NELM in a real-world setting. A clear dose-response relationship was demonstrated and future studies should aim at a Dt of ≥ 120 Gy, being predictive of response. No dose-toxicity relationship could be established.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ramdhani K, Beijer-Verduin J, Ebbers SC, et al. Dose-effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization. Eur J Nucl Med Mol Imaging. 2024. PMID: 38369678. doi:10.1007/s00259-024-06645-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。